Affiliation:
1. Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology
2. Peoples' Friendship University of Russia
Abstract
Introduction. The article provides latest data on modern methods of treating rosacea. The results of own clinical observations of patients with moderate to severe papulopustular rosacea receiving combination treatment and a comparative analysis of the efficacy of various therapy regimens are presented.Objective of the study. The aim of the study was to conduct a comparative analysis of the therapeutic efficacy of combination therapy using the ivermectin 1% topical drug combined with systemic therapy drugs (doxycycline, minocycline, isotretinoin).Materials and methods. We observed 37 patients with moderate to severe papulo-pustular rosacea subtype. The patients were divided into 4 groups (A, B, C, D). Patients in the control group received monotherapy with 1% ivemectin topical drug, patients in the other groups received combination therapy (1% ivermectin combined with low-dose doxycycline, minocycline and isotretinoin). The efficacy of the therapy was evaluated by measuring rosacea severity on the Scale for Diagnostic Assessment of Rosacea (SDAR), clinical manifestations according to the IGA (Investigator Global Assessment) criteria, and by assessing the patients' quality of life using the DLQI (Dermatology Life Quality Index) questionnaire before and after 3-month treatment.Results. The comparative analysis of changes in severity indicators of the skin process and quality of life in patients with moderate to severe papulopustular rosacea after topical and combination therapy showed that the results of the treatment in patients receiving combination therapy were more significant than those in the group receiving monotherapy.Conclusion. The concomitant use of 1% ivermectin and systemic drugs is most effective in patients with severe papulopustular rosacea subtype. The combination treatment tailored to the clinical forms and severity of rosacea allows to optimize the clinical results of the therapy, which significantly affects the patients' quality of life and opens up potential for an individual approach in the algorithms for the treatment of rosacea.
Reference27 articles.
1. Potekaev N.N. Rosacea (etiology, clinic, therapy). Moscow, St Peterburg: Binom, Nevskiy dialekt; 2000. (In Russ.)
2. Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69(6 Suppl 1):S15-S26. doi: 10.1016/j.jaad.2013.04.045.
3. Woo Y.R., Lim J.H., Cho D.H., Park H.J. Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition. Int J Mol Sci. 2016;17(9):1562. doi: 10.3390/ijms17091562.
4. Baldwin H.E. Diagnosis and treatment of rosacea: state of the art. J. Drugs. Dermatol. 2012;11(6):725-730. Available at: https://pubmed.ncbi.nlm.nih.gov/22648219.
5. Sharshunova A.A., Kruglova L.S., Kotenko K.V., Sofinskaya G.V. Etiopatho-genesis and the opportunities of laserotherapy of erythemato-teleangiectatic rosacea subtype. Fizioterapiya, bal'neologiya i reabilitatsiya = Russian Journal of the Physial Therapy, Balneotherapy and Rehabilitation. 2017;(6):284-290. (In Russ.) doi: 10.18821/1681-3456-2017-16-6-284-290.